Global drugs giant Pfizer has completed the previously-announced sale of its Pfizer Consumer Healthcare business to Johnson & Johnson for $16.6 billion or about $13.5 billion in after-tax proceeds (Marketletter July 3).
"The proceeds from this sale, combined with our strong operating cash flow, give us the flexibility to invest in the growth of our core pharmaceutical business while enhancing total return to shareholders through dividends and share purchases," said Jeffrey Kindler, Pfizer's chief executive, who has also been appointed as chairman of the group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze